Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tutukon is a phytotherapeutic (herbal) combination product developed and marketed by companies including Grand Medical Group and Laboratorios Miquel y Costas & Miquel. It is primarily indicated for the treatment and prevention of urolithiasis (kidney stones), as well as for managing urinary tract infections and providing antispasmodic and diuretic effects. The formulation typically consists of a hydroethanolic extract of several plants, including *Equisetum arvense* (Horsetail), *Spergularia rubra* (Sandspurry), *Peumus boldus* (Boldo), *Sideritis angustifolia* (Ironwort), *Opuntia ficus-indica* (Prickly pear), *Cynodon dactylon* (Bermuda grass), *Melissa officinalis* (Lemon balm), and *Rosmarinus officinalis* (Rosemary). It works through a multi-modal mechanism involving diuretic, anti-inflammatory, antispasmodic, and litholytic (stone-dissolving) properties, facilitating the excretion of urinary salts and preventing stone recurrence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tutukon.